|
GB202102001D0
|
|
Medium production of bacterial extracellular vesicles
|
|
GB202101631D0
|
|
Method of transposon insertion site sequencing with improved resolution
|
|
GB202100378D0
|
|
Methods and compositions for antibiotic potentiation
|
|
GB202019102D0
|
|
Compositions and methods for extracellur vesicle drug delivery
|
|
GB202019101D0
|
|
Method and compsoitions utilising vitamin b12 binding
|
|
GB202018713D0
|
|
Methods and compositions utilising vitamin b12 binding
|
|
GB202018717D0
|
|
Compositions and methods for extracellular vesicle drug delivery
|
|
GB202016296D0
|
|
Identification of antibiotic synergistic targets
|
|
GB202013928D0
|
|
Method and compositions for drug resistance screening
|
|
GB202006272D0
|
|
Method and identifying and obtaining live baterial isolates
|
|
GB201817194D0
|
|
Gut bacteria derived microvesicles for vaccine delivery
|
|
GB201809877D0
|
|
Sialic acid transporter proteins as biomarkers and drug targets
|
|
GB201800728D0
|
|
Enterococcus neurotoxin composition and use thereof
|
|
GB201715489D0
|
|
S-Methylcysteine sulfoxide for cancer prevention and treatment
|
|
GB201707164D0
|
|
Increased protein content of processed grain or seed biomass
|
|
CA3003561A1
|
|
Engineering gut commensal bacteria to express heterologous proteins in their outer membrane vesicles (omvs) for delivery to the gi-tract
|
